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Abstract
Coxsackievirus B3 (CVB3) is one of the most important causes of viral myocarditis. Cytokines are involved in the control of CVB3
replication and pathogenesis. Local expression of specific cytokines by recombinant CVB3 confers prevention of virus-caused myocarditis.
Expression of IFN- by CVB3(IFN-) protected BALB/c and C57BL/6 mice when the lethal infection with the highly pathogenic CVB3H3
variant was given directly after or prior to CVB3(IFN-) inoculation by decreasing the viral load and spread as well as tissue destruction.
This direct effect was not restricted to the homologous virus. In vitro, cocultivation of CVB3(IFN-)-infected cells induced a reduction of
CVB3H3 replication and virus-induced cytopathogenicity.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Cardiovascular disease is one of the major causes of
human death and has been linked to many different risk
factors. Coxsackievirus B3 (CVB3), a member of the Pi-
cornavirus family, is an important human pathogen that has
been associated with serious diseases including acute and
chronic myocarditis and pancreatitis (Baboonian et al.,
1997; Clements et al., 1995). Extensive analysis indicates
that coxsackieviruses, together with other enteroviruses of
the picornavirus family, are involved in up to 50% of acute
myocarditis and in approximately 25% of cases character-
ized by symptoms of dilated cardiomyopathy (DCM) in
humans. Each year, around 100,000 new cases of DCM are
diagnosed in the U.S.A. (Bowles et al., 1986). The presence
of CVB3 in heart tissue of patients with acute or chronic
myocarditis has been demonstrated (Kandolf et al., 1987).
However, the pathogenesis of coxsackievirus-induced hu-
man heart disease is only partly characterized so far. There-
fore, coxsackievirus-caused myocarditis has been studied
extensively in different murine models (Chow et al., 1992;
Henke et al., 1995; Huber and Pfaeffle, 1994; Leipner et al.,
1999; Mena et al., 1999; Wolfgram et al., 1986), demon-
strating that the outcome of this viral infection is determined
by complex interactions among several variables of the
virus and the host (Chow et al., 1991; Huber, 1997). Despite
the well-characterized molecular structure of coxsackievi-
ruses (Natarajan and Johnson, 1998) and the successful use
of common (Fohlman et al., 1993; See and Tilles, 1997) or
novel immunization procedures (Henke et al., 1998, 2001b)
in animal models, no virus-specific preventive procedures
against CVB3-caused myocarditis are in clinical use today.
Experimental data indicate that cytokines are involved in
controlling CVB3 replication. For example, IFN- espe-
cially was shown to be highly protective against coxsack-
ievirus-induced disease because IFN- knockout mice were
completely susceptible to this infection (Horwitz et al.,
1999). Otherwise, an organ-specific transgenic overexpres-
sion of IFN- significantly reduced CVB3 and CVB4 rep-
lication in murine pancreas tissue (Horwitz et al., 1999,
2000). The simultaneous expression of those immunoregu-
latory proteins from within the viral genome and starting
immediately with the viral replication should activate im-
mune responses much faster than during a normal course of
infection. Recently it has been demonstrated that a CVB3
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vector can produce an intact bioactive interleukin (interleu-
kin-4) under in vitro and in vivo conditions (Chapman et al.,
2000). Furthermore, the simultaneous expression of the im-
munoregulatory cytokines IL-10 and IFN-—released by
recombinant CVB3 variants (CVB3rec)—influenced the
normal pattern of immune pathways and caused an intense
protective reaction against subsequent viral infections
(Henke et al., 2001a). Four weeks after the initial infection
with CVB3rec, challenge experiments with the lethal vari-
ant CVB3H3 revealed almost complete protection against
CVB3 infections using the genetically different BALB/c or
C57BL/6 mice, depending on the virus-caused production
of functional cytokines by CVB3rec variants regardless
whether the TH1- or TH2-specific cytokines were expressed.
In addition to this indirect protective effect, the direct
cytokine-mediated influence on the replication of a highly
pathogenic CVB3 strain (CVB3H3) was analyzed under in
vivo and in vitro conditions. This study focused on (i)
challenge experiments by which the lethal infection was
given directly after or prior to the administration of
CVB3rec variants, (ii) the influence of this cytokine expres-
sion on the replication and cell destruction caused by a
homologous or heterologous coxsackievirus, and (iii) the
characterization of the putative protective mechanism via
the induction of the inducible nitric oxide synthase (iNOS).
Results
Direct protective activity in vivo
A high level of virus replication, spread to susceptible
organs, and extensive myocardial tissue damage are respon-
sible for disease and death in this murine model of CVB3-
induced myocarditis. After intraperitoneal (i.p.) infection,
viral replication starts in exocrine pancreas tissue at first.
Thereafter, infectious virus spreads via the blood circulation
to different susceptible organs, e.g., spleen and heart, caus-
ing cadiomyocyte destruction and death. One strategy to
prevent this damaging event is the application of cytokine-
expressing CVB3 variants 4 weeks prior challenge. As it
was shown before (Henke et al., 2001a), the replication of
all recombinant CVB3 variants was almost equal with re-
gard to the localization (pancreas only) and the amount of
infectious viruses, indicating an attenuated phenotype. In
contrast, CVB3wt (the parental strain of the CVB3rec vari-
ants) induced destruction of the exocrine pancreatic tissue,
and virus spread to several organs, including the heart. In
addition, only BALB/c mice—which were inoculated with
the CVB3(IFN-) variant—revealed increased serum IFN-
concentrations (65–125 pg/ml) 1 day postinfection (p.i.),
whereas in sera of all other infected mice basal IFN- levels
were present (15–70 pg/ml).
To analyze the direct preventive effect of the cytokine
expression by recombinant CVB3 variants on a lethal in-
fection with the highly pathogenic strain CVB3H3, BALB/c
as well as C57BL/6 mice were intraperitoneally inoculated
with CVB3rec variants prior to or after the CVB3H3 chal-
lenge. The CVB3(muIL-10) construct—which expresses
only a biologically inactive form of IL-10 (Henke et al.,
2001a)—was used to distinguish between the attenuated
phenotype of the CVB3rec variants and the real cytokine
effect under in vivo conditions. Mice of certain control
groups either received CVB3wt or remained noninfection.
Different mouse strains were used to demonstrate the effi-
cacy of the treatment independently of the genetic back-
ground of mice. One day later, these mice were challenged
with 100 LD50 doses (BALB/c: 16,440 PFU; C57BL/6:
52,000 PFU) of the lethal variant CVB3H3. After the chal-
lenge, the number of surviving animals was monitored up to
28 days p.i. No excess mortality was noted beyond this time.
As shown in Fig. 1, 87.5% of the CVB3(IFN-)-inoculated
BALB/c mice survived this lethal challenge. Preinjection
with CVB3(IL-10) or CVB3wt was much less protective,
because only 62.5% or 12.5% survived the CVB3H3 infec-
tion. No control mice and no mice of the CVB3(muIL-10)-
treated group were protected. The statistical analysis dem-
onstrates significant differences between the CVB3(IFN-)-
Fig. 1. Preventive effect of cytokine expression by recombinant CVB3 variants. BALB/c and C57BL/6 mice were inoculated with CVB3wt, CVB3(IFN-),
CVB3(IL-10), or CVB3(muIL-10). Control mice remained noninfected. One day later, all mice were challenged with 100 LD50 doses of CVB3H3 i.p. The
percentage of animals surviving is shown over a period of 28 days. The results presented summarize data from three independent experiments, using at least
three to four mice in each group.
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and the CVB3(IL-10)-treated mice (P  0.0014). With
C57BL/6 mice, a similar result was obtained. After
CVB3(IFN-) inoculation, 85.7% survived, whereas only
33.3% of the CVB3(IL-10) were protected. As well, the
statistical analysis demonstrates significant differences be-
tween the CVB3(IFN-)- and the CVB3(IL-10)-treated
group (P  0.00003). Mice of all other groups did not
survive the 28-day observation period.
Next, the inoculation schedule was changed in a way that
at first BALB/c or C57BL/6 mice were i.p. infected with five
LD50 doses (BALB/c: 822 PFU; C57BL/6: 2600 PFU) of
CVB3H3. Six hours later, these mice were inoculated with
106 PFU of the CVB3rec variants. Control groups either
received CVB3wt or remained noninfected. After that, the
number of surviving mice were monitored up to 4 weeks p.i.
No excess mortality was noted beyond this time. As shown
in Figs. 2A and B, up to 66% of BALB/c mice and 70% of
C57BL/6 mice—which were treated with the IFN--ex-
pressing CVB3 variant—were protected against the lethal
challenge, indicating a IFN--specific effect. The treatment
with CVB3(IL-10) caused only 30% (BALB/c) and 25%
(C57BL/6) protection, whereas mice of both strains, which
received either CVB3wt or CVB3(muIL-10), were not pro-
tected at all. The comparison of the surviving rate between
CVB3(IFN-)- and CVB3(IL-10)-inoculated BALB/c or
C57BL/6 mice revealed statistically increased values for the
CVB3(IFN-)-inoculated group: BALB/c mice: P 
0.0009; C57BL/6 mice: P  0.0004. These challenge ex-
periments clearly demonstrated that IFN- directly reduce
mortality during an ongoing acute CVB3 infection in mice.
The same experiments—carried out 24 h after the lethal
infection and with the efficient CVB3(IFN-) variant—
revealed no protection as is demonstrated in Figs. 2C and D.
However, the IFN- expression by CVB3(IFN-) delayed
the onset of this lethal disease in animals of both mouse
strains, indicating the antiviral interferon activity.
To confirm that the IFN--caused protection against
CVB3H3 was not limited to the homologous virus, the
heterologous coxsackievirus B4 (CVB4) was applied. The
CVB4 strain—used in this experimental setup—replicates
to high titers in the pancreas of BALB/c mice causing an
extensive destruction of the exocrine tissue but no death
after i.p. inoculation. An example of this observation is
demonstrated in Fig. 3A. However, when mice were inoc-
ulated with CVB3(IFN-) 24 h prior CVB4 infection, no
pancreas tissue destruction was detectable up to 4 weeks
after this second infection (Fig. 3B). In contrast, this tissue
protection was unobservable when mice were inoculated
with CVB3wt, CVB3(IL-10), or CVB3(muIL-10) 1 day
prior CVB4 infection (Figs. 3C, D, and E).
Characterization of the direct protective activity in vivo
Further experiments focused on the IFN--caused influ-
ence on CVB3H3 replication. Therefore, BALB/c mice
were i.p. inoculated with CVB3wt or CVB3(IFN-), respec-
Fig. 2. Therapeutic effect of cytokine expression by recombinant CVB3 variants. BALB/c (A and C) and C57BL/6 (B and D) mice were infected with five
LD50 doses of CVB3H3 i.p. Six hours (A and B) or 24 h (C and D) later, mice were inoculated with CVB3wt, CVB3(IFN-), CVB3(IL-10), or
CVB3(muIL-10) (A and B) or only with CVB3wt or CVB3(IFN-) (C and D). Control mice did not receive a second infection. The percentage of animals
surviving is shown over a period of 28 days. The results presented summarize data from three independent experiments, using at least three to four mice in
each group.
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tively. One group of mice remained noninfected. One day
later, all mice were infected with 100 LD50 doses of the
lethal CVB3H3 strain. Again, 1 day later, all mice were
sacrificed and the amount of infectious virus was analyzed
in different tissues, such as pancreas, spleen, and heart, as
well as in sera. As shown in Fig. 4, the virus load in control
mice—which received only the lethal challenge—and in
mice CVB3wt-inoculated before the challenge infection—
was high in pancreatic tissue and well detectable in heart,
spleen, and serum. In contrast, the virus concentration in
pancreas tissue of CVB3(IFN-)-inoculated BALB/c mice
was significantly reduced (P  0.002) and no virus was
detectable in spleen, heart, or serum. Also by RT-PCR
technique no viral RNA was found in these tissue samples
(data not shown). As expected, this effect was based on the
expression of IFN- by CVB3(IFN-), because in the
CVB3wt-inoculated group, a normal virus replication oc-
curred. Using C57BL/6 mice, basically the same results
were obtained during these challenge experiments (Fig. 4).
Again, due to the IFN- expression by CVB3(IFN-), the
virus load was significantly reduced in the pancreas (P 
0.002) and not detectable in spleen, heart, and serum. Later
on during these challenge experiments, in CVB3H3- or
CVB3wt/CVB3H3-infected BALB/c and C57BL/6 mice,
the virus load in the heart increased causing myocardial
damage and death. In contrast, in CVB3(IFN-)-treated
mice, the CVB3H3 spread to other organs was completely
inhibited. Taken together, these results indicate a direct
virus-inhibitory effect of IFN- after expression by the
recombinant virus variant CVB3(IFN-), which prevents
CVB3-induced disease.
To analyze the fate of the challenge virus after infection,
male BALB/c mice were inoculated with either CVB3wt or
CVB3(IFN-), or remained noninfected (control). One day
later, mice were challenged with 100 LD50 doses of
CVB3H3 and 1 day after this challenge, RNA was isolated
from pancreas and heart tissue. By RT-PCR procedure, the
coding sequence for the structural protein VP1 was ampli-
fied as shown in Fig. 5. Due to the fact that an unique EcoRI
restriction site is located only in the VP1 sequence of
CVB3H3, a differentiation between the viruses (CVB3H3
versus CVB3wt and CVB3H3 versus CVB3(IFN-) was
possible. In tissue of individual BALB/c mice—which were
only inoculated with the challenge virus—the obtained VP1
PCR fragment is cleaved with EcoRI into two distinct frag-
ments. In contrast, in tissue of BALB/c mice—which were
inoculated with CVB3wt or CVB3(IFN-) prior the
CVB3H3 challenge—the VP1 PCR product was not cleav-
able with EcoRI, indicating that at this time the challenge
virus was not detectable by this method. This result was
confirmed by sequence analysis. However, later during the
challenge experiments, CVB3H3 overcame this inhibition
and started to replicate in pancreas and heart tissue of mice
previously infected with CVB3wt, causing tissue destruc-
tion and death. In contrast, in heart tissue of CVB3(IFN-)/
CVB3H3-infected animals no infectious virus and no viral
RNA was detectable during the challenge period, confirm-
ing the data presented in Fig. 4.
During murine coxsackievirus infections the expression
of iNOS is well documented in several studies (Lowenstein
et al., 1996; Zaragoza et al., 1998; Glu¨ck et al., 2000),
indicating that iNOS is directly induced in certain CVB3-
infected tissue. IFN- is capable of activating iNOS (Karu-
piah et al., 1993), which may lead to the production of
nitrite oxide (NO) and thereby may prevent viral replication
by inhibiting the viral protease 2A (Badorff et al., 2000). To
analyze that the IFN- expression by CVB3(IFN-) acti-
vates the iNOS transcription early during infection, equal
RNA amounts from pancreas tissue of individual mice—
which were either inoculated with CVB3H3 alone or with
CVB3wt and 24 h later with CVB3H3 or with
CVB3(IFN-) and 24 h later with CVB3H3—were isolated,
Fig. 3. Infection with CVB4. Paraffin sections of pancreas tissue obtained from BALB/c mice were stained with hematoxylin and eosin (magnification,200).
Mice were infected with CVB4 (A) or inoculated with CVB3(IFN-) (B), CVB3wt (C), CVB3(IL-10) (E), or CVB(muIL-10) (F) 24 h prior CVB4 infection.
All samples were taken 4 weeks after the last infection. Only the exocrine pancreas tissue of CVB3(IFN-)-inoculated CVB4-infected mice remained
undamaged (B).
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DNase-treated, and reverse transcribed into cDNA. Detec-
tion of -actin mRNA confirmed that all RNA preparations
were equally well performed. Using these samples, an
iNOS-specific, nonquantitative PCR was performed, as is
demonstrated in Fig. 6. In two of three CVB3(IFN-)-
inoculated mice, the transcription of iNOS was substantially
increased in pancreas tissue at this time. However, in one of
three CVB3wt-infected mice, the transcription of iNOS was
slightly increased over the background level as well. This
experiment was repeated three times with three mice in each
group. In all three experiments two of three (66%)
CVB3(IFN-)-infected mice revealed evaluated iNOS
mRNA levels, whereas in one of three experiments the
iNOS mRNA level in tissue of CVB3wt-infected mice was
only slightly increased in one of three mice. Despite indi-
vidual differences, these results may support the observa-
tion that iNOS and therefore possibly NO could be involved
in the prevention of CVB3H3 replication.
Furthermore, the direct antiviral activity of IFN-, ex-
pressed by the recombinant CVB3(IFN-) variant, was also
characterized under in vitro coculture conditions. For these
experiments, CVB3H3-infected GMK cell monolayers were
cocultivated with GMK cells, which were either infected
Fig. 4. Quantification of infectious virus. The amount of infectious virus
particles in pancreas, serum, spleen, and heart of BALB/c as well as
C57BL/6 mice 1 day after a lethal challenge with 100 LD50 doses of
CVB3H3 is characterized by TCID50 assays. One day prior to the chal-
lenge, mice were inoculated with either CVB3wt or CVB3(IFN-), or
remained noninfected (control). Experimental groups consisted of five
mice, and experiments were repeated three times. The mean  standard
deviation is shown (n.d.: not detectable).
Fig. 5. Differentiation of inoculated virus. Male BALB/c mice were inoc-
ulated with either CVB3wt or CVB3(IFN-), or remained noninfected
(control). One day later, mice were challenged with 100 LD50 doses of
CVB3H3. One day after this challenge, RNA was isolated from the pan-
creas and heart tissue of three individual mice. By RT-PCR procedure, the
coding sequences of the structural protein VP1 and of -actin (as an
internal control) were amplified. Because a unique EcoRI restriction site is
located only in the VP1 sequence of CVB3H3, a differentiation between
the viruses (CVB3H3 versus CVB3wt and CVB3H3 versus CVB3(IFN-))
is possible (1: DNA marker; 2–4: CVB3H3 only; 5–7; CVB3wt and
CVB3H3; 8–10: CVB3(IFN-) and CVB3H3). Incubation of the CVB3H3
VP1 RT-PCR product (851 bp) with EcoRI caused the formation of two
fragments (538 and 313 bp), whereas the VP1 RT-PCR product of CVB3wt
and CVB3(IFN-) remained noncleaved.
Fig. 6. Detection of iNOS expression. Male BALB/c mice were inoculated
with either CVB3wt or CVB3(IFN-), or remained noninfected (control).
One day later, mice were challenged with 100 LD50 doses of CVB3H3.
One day after this challenge, RNA was isolated from the pancreas tissue of
three individual mice. By RT-PCR procedure, the coding sequences for
murine iNOS and for -actin (as an internal control) were amplified (1:
DNA marker; 2–4: CVB3H3 only; 5–7: CVB3wt and CVB3H3; 8–10:
CVB3(IFN-) and CVB3H3). The results presented summarize data from
three independent experiments, using at least three mice in each group.
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with CVB3wt or CVB3(IFN-). Because of the 20-nm
pores in the membrane, only proteins—such as IFN-—but
not whole virus particles were able to move between both
cell cultures during the incubation time. As was expected,
the expression of IFN- by CVB3(IFN-) caused a signif-
icant reduction of viral replication (P 0.00007) and virus-
induced cytopathogenicity (P  0.0027) in CVB3H3-in-
fected cell cultures in comparison to CVB3H3-infected
cells, which were cocultivated with CVB3wt-infected cells
24 h p.i. (Fig. 7). Incubations with different concentrations
of recombinant human IFN- reduced the viral replication
as well, whereas the addition of murine IFN- antibodies
blocked the IFN--mediated antiviral effect (data not
shown).
Discussion
According to the World Health Organization, 1.5% of
enteroviral infection and 3.2% of coxsackievirus B infec-
tions lead to cardiovascular symptoms (Grist et al., 1978).
So far, there is no preventive or therapeutically applicable
procedure in clinical use. After experimental CVB3 infec-
tion of mice, replicating viruses can be detected during the
acute stage of infection in several organs but especially in
heart and pancreas tissue. Virus-caused tissue damage and
immune activation via cytokine expression are involved in
CVB3-caused pathology (Knowlton and Badorff, 1999). As
was demonstrated before (Henke et al., 2001a), the simul-
taneous expression of cytokines such as IFN- or IL-10
from within the viral genome and starting immediately with
the viral replication activate protective immune responses
against subsequent infections (Henke et al., 2001a). Two
sites have been used successfully to insert larger foreign
nucleotide sequences into picornaviral genomes: the start of
the translation (Andino et al., 1994) and the junction of the
viral capsid protein 1D and the viral protease 2Apro (Tang
et al., 1997). Until today, several studies have described
coxsackieviral vectors to express foreign sequences (Chap-
man et al., 2000; Feuer et al., 2002; Henke et al., 2001a;
Hofling et al., 2000; Reimann et al., 1991; Slifka et al.,
2001).
IFN- is a cytokine produced by NK cells, CD4 Th1
cells, and a subset of CD8 cells. This cytokine is consid-
ered to be an important defense mechanism during the
immune response against intracellular bacteria, certain par-
asites, and viruses (Billiau, 1996). IFN- exerts two major
effects: directly inhibiting the replication of some microbes
and stimulating the cellular immune response. The direct
IFN--mediated effect is based on the induction of certain
cellular products that interfere with viral replication (Karu-
piah et al., 1993) or promote the induction of apoptosis of
infected cells (Henry et al., 1993). In CVB3-infected carrier
state cultures of human myocardial fibroblast, recombinant
IFN- and IFN- possessed a higher antiviral activity than
IFN- (Heim et al., 1996). The indirect IFN- effect on the
generation and function of specific immune effectors is very
complex, including up-regulation of antigen expression
(Geginat et al., 1997) as well as modulation of priming
(Freedman et al., 1991), recruitment (Taub et al., 1993), and
death of activated T cells (Liu and Janeway, 1990). IFN-
also exerts stimulatory effects on certain functions of mac-
rophages and NK cells (Dalton et al., 1993).
It was recently published that a tissue-specific IFN-
overexpression in pancreas of IFN--transgenic mice had an
inhibitory influence on the replication of CVB3 and CVB4
(Horwitz et al., 1999, 2000). In contrast, histopathological
changes were much more distinct in CVB3-infected IFN-
knockout mice combined with a higher lethality (Horwitz et
al., 2000). This observation is consistent with our data
demonstrating that the simultaneous and direct local pres-
ence of IFN- in CVB3-infected tissue dramatically reduces
viral replication and prevents death, even when the lethal
infection has already started. This direct effect was time-
dependent but independent from the genetic background of
the infected host or the applied virus (see Figs. 1–5). There-
fore, the observed protection of CVB3(IFN-)-inoculated
mice after the lethal challenge could be based on the cir-
cumvention of virus replication. This obvious prevention of
CVB3H3 replication can only be explained by a IFN--
based activity, because at this early time of infection, no
virus-specific antibody response was detectable (data not
shown). The result was confirmed by using CVB4-infected
animals (Fig. 3). Despite the fact that CVB3 and CVB4 are
closely related viruses, virus-specific neutralizing antibod-
ies clearly distinguish between both viruses. Prior to CVB4
infection, only the pancreas tissue of CVB3(IFN-)-inocu-
lated mice remained unharmed. Therefore, it is more likely
that an IFN--mediated interference between both viruses
occurred as it was first described many years ago for the
Fig. 7. Inhibition of CVB3wt replication by cocultivation with CVB3(IFN-
). CVBH3-infected GMK cell monolayers in 24-well cell-culture plates
were cocultivated with GMK cells, which were infected with either
CVB3wt or CVB3(IFN-). Cell monolayers were infected with a m.o.i. of
3. After 1 day of incubation, the viability (in % of noninfected control
cultures) of these CVB3H3-infected cells and the amount of infectious
virus particles in the supernatants of these cultures were determined.
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interferon-caused inhibition of viral replication (Linden-
mann, 1982).
The characterization of the nature of the replicating vi-
ruses in CVB3wt- or CVB3(IFN-)-inoculated mice 1 day
after CVB3H3 infection demonstrated, that—despite high
viral titer—the challenge virus CVB3H3 was not detectable
in pancreas and heart tissue of these mice at this time (Fig.
5). However, most of the mice—which were inoculated
with CVB3wt, CVB3(IL-10), or CVB3(muIL-10)—did not
survive the lethal CVB3H3 challenge, indicating that
CVB3H3 was able to overcome this interference during the
challenge period. In contrast, most of the CVB3(IFN-)-
inoculated mice survived the challenge, which demonstrates
the direct antiviral activity of IFN- against CVB3. IL-10
expression by CVB3(IL-10) induced some protection
against death during challenge experiments (Figs. 1, 2A and
B). This effect is based on the bioactive form of IL-10,
because inoculations with CVB3(muIL-10) were not pro-
tective at all. In addition, the expressed IL-10 revealed no
direct tissue-protective antiviral properties, because
CVB3(IL-10) was unable to protect exocrine pancreas tis-
sue after CVB4 infection (Fig. 3E) or CVB3H3 challenge
(data not shown). In contrast, the protective IFN- effect
was not virus-specific. BALB/c mice, which received a
CVB3(IFN-) inoculation 24 h prior a CVB4 infection,
were completely protected against virus-induced pancreas
destruction (Fig. 3B). Therefore, the IL-10-induced protec-
tion to prevent death during CVB3H3 challenge seems to be
indirect via the induction of other immune factors. At
present, an explanation of this observation can only be
speculative. However, it could be demonstrated that immu-
nization with a live-attenuated varicella-zoster virus vaccine
induced IL-10 production in human volunteers and was the
prerequisite for a primary immune response (Jenkins et al.,
1998).
CVB3wt inoculation—given 6 h prior CVB3H3 chal-
lenge—significantly delays death (Figs. 2A and B). An
explanation for this observation could be that five LD50
doses of CVB3H3 equals only 822 PFU (BALB/c) and 2600
PFU (C57BL/6), respectively. After 6 h the first round of
CVB3H3 replication was not completed. Six hours after the
i.p. administration of this relatively small virus amount, 106
PFU CVB3wt or the CVB3rec variants were i.p. inoculated
as well. Under in vitro and in vivo conditions the replication
capacity of CVB3wt and CVB3H3 is equal, but CVB3wt is
by far less lethal than CVB3H3 in mice. Because of the
imbalance between the inoculated virus amounts, the initial
CVB3H3 replication was affected which could be respon-
sible for the delay of death in these experimental groups.
This effect was not detectable when the time between both
inoculations was extended to 24 h (Figs. 2C and D). Due to
the insertion of additional gene sequences, all recombinant
CVB3 variants revealed decreased replication capacities
(Henke et al., 2001a). Therefore, using mice, which re-
ceived 106 PFU of CVB3rec variants 6 h after the challenge,
this inhibitory impact was not observable.
One important antiviral effect of IFN- consists of in-
duction of the iNOS (Harris et al., 1995), which catalyzes
the formation of NO from L-arginine. This bioreactive mol-
ecule possesses regulative and cytoprotective as well as
antiviral activities. During cell-culture experiments (Zara-
goza et al., 1997) and murine coxsackievirus infections
(Lowenstein et al., 1996; Zaragoza et al., 1998; Glu¨ck et al.,
2000), the expression of iNOS was well documented in
several studies indicating that (i) iNOS is directly induced in
certain virus-infected tissue (Mikami et al., 1996); (ii) iNOS
protects mice against viral replication (Zaragoza et al.,
1999; Flodstrom et al., 2001); but (iii) iNOS may also cause
a NO-dependent cytotoxic effect (Bevan et al., 2001). How-
ever, an direct inhibitory effect of NO on proteases 2A and
3C of CVB3 has been published recently (Badorff et al.,
2002; Saura et al., 1999). Furthermore, iNOS knockout
mice revealed an increased mortality rate following cox-
sackieviral infection in comparison to normal mice (Flod-
strom et al., 2001). Our data emphasize these previous
results. As is shown in Fig. 6, increased transcriptional
activity of iNOS was detectable in two of three individual
mice, which received CVB3(IFN-) prior to the lethal chal-
lenge. In pancreas tissue of one of three CVB3wt-infected
mice marginally increased activity was present as well in
comparison to the control group. Despite these individual
differences, this iNOS induction followed by NO synthesis
could be involved in the direct protective activity of IFN-
produced by CVB3(IFN-). Further experiments are fo-
cused on that observation. However, in our coculture system
(Fig. 7), the virus-replication in the CVB3H3-infected com-
partment was not completely inhibited by the IFN- release,
indicating that under in vivo conditions additional antiviral
activities were induced.
Materials and methods
Mice
Male inbred BALB/c (H-2dd) and C57BL/6 (H-2bb)
mice—7–9 weeks of age—were used in this study. Exper-
imental groups consisted of a minimum of three to four
mice, and experiments were repeated usually three or four
times. Animal experiments complied with all federal per-
missions, guidelines, and institutional policies.
Viruses and cell lines
The CVB3 variants used were cDNA-generated viruses
obtained after transfection of GMK cells with the plasmids
pCVB3wt (Lindberg et al., 1992), pCVB3M2(IFN-)
(Henke et al., 2001a), pCVB3M2(IL-10) (Henke et al.,
2001a), pCVB3(muIL-10) (Henke et al., 2001a), or pBK-
CMV/CVB3H3 (Knowlton et al., 1996). The CVB4 strain
JVB was obtained from its own common virus stock. All
viruses were propagated in GMK cells and quantified by
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standard plaque formation assay on GMK cell monolayers
as described previously (Henke et al., 1995).
Infection protocol
Mice were inoculated by i.p. injection of 0.2 ml saline
containing the stated amount of virus and were monitored
daily for morbidity and mortality up to 4 weeks p.i.
Challenge experiments
According to the stated time of the initial infection with
CVB3wt or recombinant CVB3 variants, all surviving mice
were challenged with 5 or 100 LD50 doses of the lethal
CVB3H3 variant by i.p. infection. Age-matched control
mice, which were not infected during the first set of exper-
iments, were used to verify the outcome of the lethal chal-
lenge. Mice were monitored daily for morbidity and mor-
tality up to 4 weeks p.i. The statistical comparisons were
carried out with Microsoft Excel by using Student’s t test.
Virus titer in organs
At different days p.i., organs were aseptically obtained,
washed with sterile saline, and homogenized with cell-
culture medium (DMEM) containing 50 U of penicillin and
50 mM streptomycin per milliliter. Cell debris was removed
by centrifugation and supernatants were subjected to se-
quential 10-fold dilutions in DMEM. The virus titer was
determined by tissue culture infectious dose 50% (TCID50)
assays. The statistical comparisons were carried out with
Microsoft Excel by using Student’s t test.
Preparation and staining of routine histology
Aseptically removed pancreas and heart tissue were fixed
with 4% formaline and mounted in paraffin, and 6-m
sections were cut and stained with hematoxylin-eosin or
with Sirius red.
RT-PCR
RNA was isolated from pancreas of infected and nonin-
fected BALB/c mice according to the acid guanidinium
thiocyanate phenol chloroform method (Chomczynski and
Sacchi, 1987) and described in detail in Henke et al. (2000).
The detection of viral genomes was performed by RT-PCR
using a primer pair which corresponds to the position 2453–
2474 and 3283–3304 of the original cDNA giving a 851-bp
PCR product. The EcoRI restriction site is located at posi-
tion 2766 in the cDNA sequence of CVB3H3. For the
murine iNOS detection, a commercially available primer
pair (Clontech Laboratory) was used, amplifying a 496-bp
PCR product.
Coculture experiments
GMK cell monolayers were prepared in 24-well cell-
culture plates and 0.02-m anapore membrane tissue cul-
ture inserts (Nalge Nunc Internation). These inserts were
placed on the top of monolayers in 24-well plates. GMK
cells in 24-well plates were infected with a multiplicity of
infection (m.o.i.) of 3 or remained noninfected (control).
Cell cultures in the insert were either infected with 3 m.o.i.
CVB3wt or CVB3(IFN-) or remained noninfected. One
day later, the amount of infectious virus particles in the
24-well compartment was analyzed by TCID50 assays. The
viability of the remaining GMK cells in the 24-well com-
partment was characterized by crystal violet staining.
Briefly, culture supernatants were removed; the monolayers
were washed twice with PBS, and crystal violet (0.2% in
20% methanol, 3.5% formaline) was added for 2 h. There-
after, plates were washed and dried, and the dye was ex-
tracted and dissolved for 30 min in 30.5 mM sodium citrate
and 0.0195 N HCl in 47.5% ethanol at pH 4.2. The optical
density (OD) of the extracted dye was measured at 490 nm.
Viability is expressed as an index in which the staining of
noninfected control cultures was set as 100%. Control cul-
tures of noninfected GMK cell monolayers in the 24-well
compartment confirmed that no virus spread occurred from
the insert during the observation period.
Acknowledgments
We thank Beate Menzel, Birgit Meiner, and Birgit
Schikowski for excellent technical assistance. Furthermore,
we thank Kirk Knowlton (UCSD, San Diego, CA, USA) for
providing the cDNA of the CVB3H3 variant. This work was
partly supported by Grant HE 2910/4-1 from the Deutsche
Forschungsgemeinschaft.
References
Andino, R., Silvera, D., Suggett, S.D., Achacoso, P.L., Miller, C.J., Bal-
timore, D., Feinberg, M.B., 1994. Engineering poliovirus as a vaccine
vector for the expression of diverse antigens. Science 265, 1448–1451.
Baboonian, C., Davies, M.J., Booth, J.C., McKenna, W.J., 1997. Coxsackie
B viruses and human heart disease. Curr. Top. Microbiol. Immunol.
223, 31–52.
Badorff, C., Fichtlscherer, B., Muelsch, A., Zeiher, A.M., Dimmeler, S.,
2002. Selective delivery of nitric oxide to a cellular target: a
pseudosubstrate-coupled dinitrosyl-iron complex inhibits the enterovi-
ral protease 2A. Nitric Oxide 6, 305–312.
Badorff, C., Fichtlscherer, B., Rhoads, R.E., Zeiher, A.M., Muelsch, A.,
Dimmeler, S., Knowlton, K.U., 2000. Nitric oxide inhibits dystrophin
proteolysis by coxsackieviral protease 2A through S-nitrosylation: a
protective mechanism against enteroviral cardiomyopathy. Circulation
102, 2276–2281.
Bevan, A.L., Zhang, H., Li, Y., Archard, L.C., 2001. Nitric oxide and
Coxsackievirus B3 myocarditis: differential expression of inducible
nitric oxide synthase in mouse heart after infection with virulent or
attenuated virus. J. Med. Virol. 64, 175–182.
342 A. Henke et al. / Virology 315 (2003) 335–344
Billiau, A., 1996. Interferon-gamma: biology and role in pathogenesis.
Adv. Immunol. 62, 61–130.
Bot, A., Bot, S., Bona, C.A., 1998. Protective role of gamma interferon
during the recall response to influenza virus. J. Virol. 72, 6637–6645.
Bowles, N.E., Richardson, P.J., Olsen, E.G., Archard, L.C., 1986. Detec-
tion of Coxsackie-B-virus-specific RNA sequences in myocardial bi-
opsy samples from patients with myocarditis and dilated cardiomyop-
athy. Lancet 1, 1120–1123.
Chapman, N.M., Kim, K.S., Tracy, S., Jackson, J., Hofling, K., Leser, J.S.,
Malone, J., Kolbeck, P., 2000. Coxsackievirus expression of the murine
secretory protein interleukin-4 induces increased synthesis of immuno-
globulin G1 in mice. J. Virol. 74, 7952–7962.
Chomczynski, P., Sacchi, N., 1987. Single-step method of RNA isolation
by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal.
Biochem. 162, 156–159.
Chow, L.H., Beisel, K.W., McManus, B.M., 1992. Enteroviral infection of
mice with severe combined immunodeficiency. Evidence for direct
viral pathogenesis of myocardial injury. Lab. Invest. 66, 24–31.
Chow, L.H., Gauntt, C.J., McManus, B.M., 1991. Differential effects of
myocarditic variants of Coxsackievirus B3 in inbred mice. A patho-
logic characterization of heart tissue damage. Lab. Invest. 64, 55–64.
Clements, G.B., Galbraith, D.N., Taylor, K.W., 1995. Coxsackie B virus
infection and onset of childhood diabetes. Lancet 346, 221–223.
Curiel, R.E., Mason, K.M., Dryden, T.D., Maurer, M.J., Bigley, N.J., 1998.
Cytokines produced early in picornavirus infection reflect resistance or
susceptibility to disease. J. Interferon Cytokine Res. 18, 587–596.
Dalton, D.K., Pitts-Meek, S., Keshav, S., Figari, I.S., Bradley, A., Stewart,
T.A., 1993. Multiple defects of immune cell function in mice with
disrupted interferon-gamma genes. Science 259, 1739–1742.
Feuer, R., Mena, I., Pagarigan, R., Slifka, M.K., Whitton, J.L., 2002. Cell
cycle status affects coxsackievirus replication, persistence, and reacti-
vation in vitro. J. Virol. 76, 4430–4440.
Flodstrom, M., Horwitz, M.S., Maday, A., Balakrishna, D., Rodriguez, E.,
Sarvetnick, N., 2001. A critical role for inducible nitric oxide synthase
in host survival following coxsackievirus B4 infection. Virology 281,
205–215.
Fohlman, J., Pauksen, K., Morein, B., Bjare, U., Ilback, N.G., Friman, G.,
1993. High yield production of an inactivated coxsackie B3 adjuvant
vaccine with protective effect against experimental myocarditis. Scand.
J. Infect. Dis. Suppl. 88, 103–108.
Freedman, A.S., Freeman, G.J., Rhynhart, K., Nadler, L.M., 1991. Selec-
tive induction of B7/BB-1 on interferon-gamma stimulated monocytes:
a potential mechanism for amplification of T cell activation through the
CD28 pathway. Cell Immunol. 137, 429–437.
Geginat, G., Ruppert, T., Hengel, H., Holtappels, R., Koszinowski, U.H.,
1997. IFN-gamma is a prerequisite for optimal antigen processing of
viral peptides in vivo. J. Immunol. 158, 3303–3310.
Glu¨ck, B., Merkle, I., Dornberger, G., Stelzner, A., 2000. Expression of
inducible nitric oxide synthase in experimental viral myocarditis. Herz
25, 255–260.
Grist, N.R., Bell, E.J., Assaad, F., 1978. Enteroviruses in human disease.
Prog. Med. Virol. 24, 114–157.
Harris, N., Buller, R.M., Karupiah, G., 1995. Gamma interferon-induced,
nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol.
69, 910–915.
Heim, A., Stille-Siegener, M., Pring-Akerblom, P., Grumbach, I., Brehm,
C., Kreuzer, H., Figulla, H.R., 1996. Recombinant interferons beta and
gamma have a higher antiviral activity than interferon-alpha in cox-
sackievirus B3-infected carrier state cultures of human myocardial
fibroblasts. J. Interferon Cytokine Res. 16, 283–287.
Henke, A., Huber, S., Stelzner, A., Whitton, J.L., 1995. The role of CD8
T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 69,
6720–6728.
Henke, A., Launhardt, H., Klement, K., Stelzner, A., Zell, R., Munder, T.,
2000. Apoptosis in coxsackievirus B3-caused diseases: interaction be-
tween the capsid protein VP2 and the proapoptotic protein siva. J. Vi-
rol. 74 (9), 4284–4290.
Henke, A., Wagner, E., Whitton, J.L., Zell, R., Stelzner, A., 1998. Protec-
tion of mice against lethal coxsackievirus B3 infection by using DNA
immunization. J. Virol. 72, 8327–8331.
Henke, A., Zell, R., Ehrlich, G., Stelzner, A., 2001a. Expression of immu-
noregulatory cytokines by recombinant coxsackievirus B3 variants
confers protection against virus-caused myocarditis. J. Virol. 75, 8187–
8194.
Henke, A., Zell, R., Stelzner, A., 2001b. DNA vaccine-mediated immune
responses in Coxsackie virus B3-infected mice. Antiviral Res. 49,
49–54.
Henry, Y., Lepoivre, M., Drapier, J.C., Ducrocq, C., Boucher, J.L., Guis-
sani, A., 1993. EPR characterization of molecular targets for NO in
mammalian cells and organelles. FASEB J. 7, 1124–1134.
Hofling, K., Tracy, S., Chapman, N., Kim, K.S., Smith Leser, J., 2000.
Expression of an antigenic adenovirus epitope in a group B coxsack-
ievirus. J. Virol. 74, 4570–4578.
Horwitz, M.S., Krahl, T., Fine, C., Lee, J., Sarvetnick, N., 1999. Protection
from lethal coxsackievirus-induced pancreatitis by expression of
gamma interferon. J. Virol. 73, 1756–1766.
Horwitz, M.S., La Cava, A., Fine, C., Rodriguez, E., Ilic, A., Sarvetnick,
N., 2000. Pancreatic expression of interferon-gamma protects mice
from lethal coxsackievirus B3 infection and subsequent myocarditis.
Nat. Med. 6, 693–697.
Huber, S.A., 1997. Coxsackievirus-induced myocarditis is dependent on
distinct immunopathogenic responses in different strains of mice. Lab.
Invest. 76, 691–701.
Huber, S.A., Pfaeffle, B., 1994. Differential Th1 and Th2 cell responses in
male and female BALB/c mice infected with coxsackievirus group B
type 3. J. Virol. 68, 5126–5132.
Jenkins, D.E., Redman, R.L., Lam, E.M., Liu, C., Lin, I., Arvin, A.M.,
1998. Interleukin (IL)-10, IL-12, and interferon-gamma production in
primary and memory immune responses to varicella-zoster virus. J. In-
fect. Dis. 178, 940–948.
Kandolf, R., Ameis, D., Kirschner, P., Canu, A., Hofschneider, P.H., 1987.
In situ detection of enteroviral genomes in myocardial cells by nucleic
acid hybridization: an approach to the diagnosis of viral heart disease.
Proc. Natl. Acad. Sci. USA 84, 6272–6276.
Karupiah, G., Xie, Q.W., Buller, R.M., Nathan, C., Duarte, C., MacMick-
ing, J.D., 1993. Inhibition of viral replication by interferon-gamma-
induced nitric oxide synthase. Science 261, 1445–1448.
Knowlton, K.U., Badorff, C., 1999. The immune system in viral myocar-
ditis: maintaining the balance. Circ. Res. 85, 559–561.
Knowlton, K.U., Jeon, E.S., Berkley, N., Wessely, R., Huber, S., 1996. A
mutation in the puff region of VP2 attenuates the myocarditic pheno-
type of an infectious cDNA of the Woodruff variant of coxsackievirus
B3. J. Virol. 70, 7811–7818.
Leipner, C., Borchers, M., Merkle, I., Stelzner, A., 1999. Coxsackievirus
B3-induced myocarditis in MHC class II-deficient mice. J. Hum. Virol.
2, 102–114.
Lindberg, A.M., Crowell, R.L., Zell, R., Kandolf, R., Pettersson, U., 1992.
Mapping of the RD phenotype of the Nancy strain of coxsackievirus
B3. Virus Res. 24, 187–196.
Lindenmann, J., 1982. From interference to interferon: a brief historical
introduction. Philos. Trans. R. Soc. Lond. B Biol. Sci. 299, 3–6.
Liu, Y., Janeway Jr., C.A., 1990. Interferon gamma plays a critical role in
induced cell death of effector T cell: a possible third mechanism of
self-tolerance. J. Exp. Med. 172, 1735–1739.
Lowenstein, C.J., Hill, S.L., Lafond-Walker, A., Wu, J., Allen, G., Lan-
davere, M., Rose, N.R., Herskowitz, A., 1996. Nitric oxide inhibits
viral replication in murine myocarditis. J. Clin. Invest. 97, 1837–1843.
Mena, I., Perry, C.M., Harkins, S., Rodriguez, F., Gebhard, J., Whitton,
J.L., 1999. The role of B lymphocytes in coxsackievirus B3 infection.
Am. J. Pathol. 155, 1205–1215.
Mikami, S., Kawashima, S., Kanazawa, K., Hirata, K., Katayama, Y.,
Hotta, H., Hayashi, Y., Ito, H., Yokoyama, M., 1996. Expression of
nitric oxide synthase in a murine model of viral myocarditis induced by
coxsackievirus B3. Biochem. Biophys. Res. Commun. 220, 983–989.
343A. Henke et al. / Virology 315 (2003) 335–344
Natarajan, P., Johnson, J.E., 1998. Molecular packing in virus crystals:
geometry, chemistry, and biology. J. Struct. Biol. 121, 295–305.
Reimann, B.Y., Zell, R., Kandolf, R., 1991. Mapping of a neutralizing
antigenic site of Coxsackievirus B4 by construction of an antigen
chimera. J. Virol. 65, 3475–3480.
Saura, M., Zaragoza, C., McMillan, A., Quick, R.A., Hohenadl, C., Lo-
wenstein, J.M., Lowenstein, C.J., 1999. An antiviral mechanism of
nitric oxide: inhibition of a viral protase. Immunity 10, 21–28.
See, D.M., Tilles, J.G., 1997. Occurrence of coxsackievirus hepatitis in
baby rabbits and protection by a formalin-inactivated polyvalent vac-
cine. Proc. Soc. Exp. Biol. Med. 216, 52–56.
Slifka, M.K., Pagarigan, R., Mena, I., Feuer, R., Whitton, J.L., 2001. Using
recombinant coxsackievirus B3 to evaluate the induction and protective
efficacy of CD8 T cells during picornavirus infection. J. Virol. 75,
2377–2387.
Tang, S., van Rij, R., Silvera, D., Andino, R., 1997. Toward a poliovirus-
based simian immunodeficiency virus vaccine: correlation between
genetic stability and immunogenicity. J. Virol. 71, 7841–7850.
Taub, D.D., Lloyd, A.R., Conlon, K., Wang, J.M., Ortaldo, J.R., Harada,
A., Matsushima, K., Kelvin, D.J., Oppenheim, J.J., 1993. Recombinant
human interferon-inducible protein 10 is a chemoattractant for human
monocytes and T lymphocytes and promotes T cell adhesion to endo-
thelial cells. J. Exp. Med. 177, 1809–1814.
Taylor, L.A., Carthy, C.M., Yang, D., Saad, K., Wong, D., Schreiner, G.,
Stanton, L.W., McManus, B.M., 2000. Host gene regulation during
coxsackievirus B3 infection in mice: assessment by microarrays. Circ.
Res. 87, 328–334.
Wolfgram, L.J., Beisel, K.W., Herskowitz, A., Rose, N.R., 1986. Varia-
tions in the susceptibility to Coxsackievirus B3-induced myocarditis
among different strains of mice. J. Immunol. 136, 1846–1852.
Yang, D., Yu, J., Luo, Z., Carthy, C.M., Wilson, J.E., Liu, Z., McManus,
B.M., 1999. Viral myocarditis: identification of five differentially ex-
pressed genes in coxsackievirus B3-infected mouse heart. Circ. Res.
84, 704–712.
Zaragoza, C., Ocampo, C.J., Saura, M., Bao, C., Leppo, M., Lafond-
Walker, A., Thiemann, D.R., Hruban, R., Lowenstein, C.J., 1999.
Inducible nitric oxide synthase protection against coxsackievirus pan-
creatitis. J. Immunol. 163, 5497–5504.
Zaragoza, C., Ocampo, C., Saura, M., Leppo, M., Wei, X.Q., Quick, R.,
Moncada, S., Liew, F.Y., Lowenstein, C.J., 1998. The role of inducible
nitric oxide synthase in the host response to Coxsackievirus myocar-
ditis. Proc. Natl. Acad. Sci. USA 95, 2469–2474.
Zaragoza, C., Ocampo, C.J., Saura, M., McMillan, A., Lowenstein, C.J.,
1997. Nitric oxide inhibition of coxsackievirus replication in vitro.
J. Clin. Invest. 100, 1760–1767.
344 A. Henke et al. / Virology 315 (2003) 335–344
